Disitamab vedotin
A monoclonal antibody used in cancer treatment
| Disitamab vedotin | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Disitamab vedotin is an antibody-drug conjugate (ADC) used in the treatment of certain types of cancer. It is a targeted therapy that combines a monoclonal antibody with a cytotoxic agent, allowing for the selective delivery of the drug to cancer cells.
Mechanism of Action[edit | edit source]
Disitamab vedotin is designed to target the human epidermal growth factor receptor 2 (HER2), which is overexpressed in some cancer cells. The monoclonal antibody component of disitamab vedotin binds to HER2 on the surface of cancer cells. Once bound, the ADC is internalized by the cell, and the cytotoxic agent, monomethyl auristatin E (MMAE), is released. MMAE disrupts the microtubule network within the cell, leading to cell cycle arrest and apoptosis.
Clinical Use[edit | edit source]
Disitamab vedotin is primarily used in the treatment of HER2-positive cancers, including certain types of breast cancer and gastric cancer. It is particularly useful in cases where the cancer has become resistant to other HER2-targeted therapies.
Development and Approval[edit | edit source]
Disitamab vedotin was developed by RemeGen, a biotechnology company based in China. It has undergone various clinical trials to assess its efficacy and safety in treating HER2-positive cancers. The drug has been approved for use in China and is undergoing further studies to expand its indications and approval in other countries.
Side Effects[edit | edit source]
As with many cancer therapies, disitamab vedotin can cause a range of side effects. Common side effects include fatigue, nausea, peripheral neuropathy, and neutropenia. More serious side effects can occur, and patients receiving this treatment are closely monitored by healthcare professionals.
Research and Future Directions[edit | edit source]
Ongoing research is focused on expanding the use of disitamab vedotin to other types of HER2-expressing tumors and improving its efficacy and safety profile. Combination therapies with other anticancer agents are also being explored to enhance treatment outcomes.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
